Elevar Therapeutics Entered into a License Agreement with Jiangsu Hengrui Pharma for Camrelizumab + Rivoceranib for Unresectable Hepatocellular Carcinoma
Shots:
- Hengrui Pharma will receive ~$600M in sales milestones along with royalty on camrelizumab net sales. Elevar gets the rights to commercialize & develop Hengrui Pharma’s camrelizumab (anti-PD-1 Ab) in combination with rivoceranib for uHCC globally excl. Greater China Region & Korea
- Elevar maintains development rights to rivoceranib outside of China & Korea. In May, Elevar and Hengrui Pharma submitted an NDA and BLA for the combination of rivoceranib & camrelizumab as 1L therapy for uHCC with anticipated PDUFA dates in May 2024
- Camrelizumab, a humanized mAb targeting PD-1 & was approved under the brand name AiRuiKa for 8 indications in China. The therapy received ODD from the US FDA for advanced HCC in April 2021
Ref: Elevar Therapeutics | Image: Elevar Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
